Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study - Concepedia

Concepedia

Publication | Open Access

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

DOI Full Paper Access

359

Citations

27

References

2018

Year

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, Joachim Sieper, Pentti A. Järvinen, Lai‐Shan Tam, Carlo Salvarani, Tae‐Hwan Kim, Alan M. Solinger, Yakov Datsenko,

Annals of the Rheumatic Diseases

Abstract

NCT02047110; Pre-results.

References

	Year	Citations

Page 1